Evolutionary therapy (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Evolutionary therapy" in English language version.

refsWebsite

Global rank English rank

4^th place

4^th place

2^nd place

2^nd place

18^th place

17^th place

5semanticscholar.org

11^th place

8^th place

low place

low place

69^th place

59^th place

621^st place

380^th place

arxiv.org

Iram, S. (2021). "Controlling the speed and trajectory of evolution with counterdiabatic driving". Nature Physics. 17: 135–142. arXiv:1912.03764. doi:10.1038/s41567-020-0989-3.

doi.org

Greaves M, Maley CC (January 2012). "Clonal evolution in cancer". Nature. 481 (7381): 306–313. Bibcode:2012Natur.481..306G. doi:10.1038/nature10762. PMC 3367003. PMID 22258609.
Davies J, Davies D (September 2010). "Origins and evolution of antibiotic resistance". Microbiology and Molecular Biology Reviews. 74 (3): 417–433. doi:10.1128/MMBR.00016-10. PMC 2937522. PMID 20805405.
Gatenby RA, Brown JS (November 2020). "Integrating evolutionary dynamics into cancer therapy". Nature Reviews. Clinical Oncology. 17 (11): 675–686. doi:10.1038/s41571-020-0411-1. PMID 32699310. S2CID 220681064.
Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (October 2013). "Cancer drug resistance: an evolving paradigm". Nature Reviews. Cancer. 13 (10): 714–726. doi:10.1038/nrc3599. PMID 24060863. S2CID 24719097.
Gillies RJ, Verduzco D, Gatenby RA (June 2012). "Evolutionary dynamics of carcinogenesis and why targeted therapy does not work". Nature Reviews. Cancer. 12 (7): 487–493. doi:10.1038/nrc3298. PMC 4122506. PMID 22695393.
Gatenby RA (May 2009). "A change of strategy in the war on cancer". Nature. 459 (7246): 508–509. Bibcode:2009Natur.459..508G. doi:10.1038/459508a. PMID 19478766. S2CID 205046753.
"CROSS resistance to antibiotics". Journal of the American Medical Association. 148 (6): 470–471. February 1952. doi:10.1001/jama.1952.02930060052015. PMID 14888510.
Santos-Lopez, Alfonso; Marshall, Christopher W; Haas, Allison L; Turner, Caroline; Rasero, Javier; Cooper, Vaughn S (25 August 2021). "The roles of history, chance, and natural selection in the evolution of antibiotic resistance". eLife. 10: e70676. doi:10.7554/eLife.70676. PMC 8412936. PMID 34431477.
Maltas J, Wood KB (October 2019). "Pervasive and diverse collateral sensitivity profiles inform optimal strategies to limit antibiotic resistance". PLOS Biology. 17 (10): e3000515. doi:10.1371/journal.pbio.3000515. PMC 6834293. PMID 31652256.
Acar A, Nichol D, Fernandez-Mateos J, Cresswell GD, Barozzi I, Hong SP, et al. (April 2020). "Exploiting evolutionary steering to induce collateral drug sensitivity in cancer". Nature Communications. 11 (1): 1923. Bibcode:2020NatCo..11.1923A. doi:10.1038/s41467-020-15596-z. PMC 7174377. PMID 32317663.
Iram, S. (2021). "Controlling the speed and trajectory of evolution with counterdiabatic driving". Nature Physics. 17: 135–142. arXiv:1912.03764. doi:10.1038/s41567-020-0989-3.
Weaver, D. (2024). "Reinforcement Learning informs optimal treatment strategies to limit antibiotic resistance". Proceedings of the National Academy of Sciences. 121.16: e2303165121. doi:10.1073/pnas.2303165121. PMC 11032439.
Enriquez-Navas PM, Kam Y, Das T, Hassan S, Silva A, Foroutan P, et al. (February 2016). "Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer". Science Translational Medicine. 8 (327). 327ra24. doi:10.1126/scitranslmed.aad7842. PMC 4962860. PMID 26912903.
Kim E, Brown JS, Eroglu Z, Anderson AR (February 2021). "Adaptive Therapy for Metastatic Melanoma: Predictions from Patient Calibrated Mathematical Models". Cancers. 13 (4): 823. doi:10.3390/cancers13040823. PMC 7920057. PMID 33669315.
Gatenby RA, Silva AS, Gillies RJ, Frieden BR (June 2009). "Adaptive therapy". Cancer Research. 69 (11): 4894–4903. doi:10.1158/0008-5472.CAN-08-3658. PMC 3728826. PMID 19487300.
Cunningham J, Brown J, Gatenby R, Stankova K (December 2018). "Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer". JAMA Oncology. 459: 67–78. Bibcode:2018JThBi.459...67C. doi:10.1016/j.jtbi.2018.09.022. PMID 30243754. S2CID 52340340.
Zhang J, Cunningham JJ, Brown JS, Gatenby RA (November 2017). "Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer". Nature Communications. 8 (1): 1816. Bibcode:2017NatCo...8.1816Z. doi:10.1038/s41467-017-01968-5. PMC 5703947. PMID 29180633.
Zhang J, Cunningham JJ, Brown JS, Gatenby RA (June 2022). "Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes". eLife. 11. doi:10.7554/eLife.76284. PMC 9239688. PMID 35762577.
Basanta D, Gatenby RA, Anderson AR (April 2012). "Exploiting evolution to treat drug resistance: combination therapy and the double bind". Mol Pharm. 9 (4): 914–921. doi:10.1021/mp200458e. PMC 3325107. PMID 22369188.
Gatenby R, Brown J, Vincent T (September 2014). "Lessons from applied ecology: cancer control using an evolutionary double bind". Cancer Research. 69 (19): 7499–7502. doi:10.1158/0008-5472.CAN-09-1354. PMID 19752088.
Gatenby RA, Artzy-Randrup Y, Epstein T, Reed DR, Brown JS (February 2021). "Eradicating Metastatic Cancer and the Eco-Evolutionary Dynamics of Anthropocene Extinctions". Cancer Research. 80 (3): 613–623. doi:10.1158/0008-5472.CAN-19-1941. PMC 7771333. PMID 31772037.
Gatenby RA, Zhang J, Brown JS (July 2019). "First Strike–Second Strike Strategies in Metastatic Cancer: Lessons from the Evolutionary Dynamics of Extinction". Cancer Research. 79 (13): 3174–3177. doi:10.1158/0008-5472.CAN-19-0807. PMC 6606376. PMID 31221821.
Wölfl B, Te Rietmole H, Salvioli M, Kaznatcheev A, Thuijsman F, Brown JS, et al. (2021). "The Contribution of Evolutionary Game Theory to Understanding and Treating Cancer". Dynamic Games and Applications. 12 (2): 313–342. doi:10.1007/s13235-021-00397-w. PMC 9117378. PMID 35601872. S2CID 239673089.
Zhang J, Cunningham JJ, Brown JS, Gatenby RA (November 2017). "Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer". Nature Communications. 8 (1): 1816. Bibcode:2017NatCo...8.1816Z. doi:10.1038/s41467-017-01968-5. PMC 5703947. PMID 29180633.
Mistry HB (January 2021). "On the reporting and analysis of a cancer evolutionary adaptive dosing trial". Nature Communications. 12 (1): 316. Bibcode:2021NatCo..12..316M. doi:10.1038/s41467-020-20174-4. PMC 7804309. PMID 33436546.

harvard.edu

ui.adsabs.harvard.edu

Greaves M, Maley CC (January 2012). "Clonal evolution in cancer". Nature. 481 (7381): 306–313. Bibcode:2012Natur.481..306G. doi:10.1038/nature10762. PMC 3367003. PMID 22258609.
Gatenby RA (May 2009). "A change of strategy in the war on cancer". Nature. 459 (7246): 508–509. Bibcode:2009Natur.459..508G. doi:10.1038/459508a. PMID 19478766. S2CID 205046753.
Acar A, Nichol D, Fernandez-Mateos J, Cresswell GD, Barozzi I, Hong SP, et al. (April 2020). "Exploiting evolutionary steering to induce collateral drug sensitivity in cancer". Nature Communications. 11 (1): 1923. Bibcode:2020NatCo..11.1923A. doi:10.1038/s41467-020-15596-z. PMC 7174377. PMID 32317663.
Cunningham J, Brown J, Gatenby R, Stankova K (December 2018). "Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer". JAMA Oncology. 459: 67–78. Bibcode:2018JThBi.459...67C. doi:10.1016/j.jtbi.2018.09.022. PMID 30243754. S2CID 52340340.
Zhang J, Cunningham JJ, Brown JS, Gatenby RA (November 2017). "Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer". Nature Communications. 8 (1): 1816. Bibcode:2017NatCo...8.1816Z. doi:10.1038/s41467-017-01968-5. PMC 5703947. PMID 29180633.
Zhang J, Cunningham JJ, Brown JS, Gatenby RA (November 2017). "Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer". Nature Communications. 8 (1): 1816. Bibcode:2017NatCo...8.1816Z. doi:10.1038/s41467-017-01968-5. PMC 5703947. PMID 29180633.
Mistry HB (January 2021). "On the reporting and analysis of a cancer evolutionary adaptive dosing trial". Nature Communications. 12 (1): 316. Bibcode:2021NatCo..12..316M. doi:10.1038/s41467-020-20174-4. PMC 7804309. PMID 33436546.

moffitt.org

labpages.moffitt.org

"Evolutionary Therapy". Moffitt Cancer Center. Open Publishing. Retrieved 2022-02-25.

nih.gov

pubmed.ncbi.nlm.nih.gov

Greaves M, Maley CC (January 2012). "Clonal evolution in cancer". Nature. 481 (7381): 306–313. Bibcode:2012Natur.481..306G. doi:10.1038/nature10762. PMC 3367003. PMID 22258609.
Davies J, Davies D (September 2010). "Origins and evolution of antibiotic resistance". Microbiology and Molecular Biology Reviews. 74 (3): 417–433. doi:10.1128/MMBR.00016-10. PMC 2937522. PMID 20805405.
Gatenby RA, Brown JS (November 2020). "Integrating evolutionary dynamics into cancer therapy". Nature Reviews. Clinical Oncology. 17 (11): 675–686. doi:10.1038/s41571-020-0411-1. PMID 32699310. S2CID 220681064.
Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (October 2013). "Cancer drug resistance: an evolving paradigm". Nature Reviews. Cancer. 13 (10): 714–726. doi:10.1038/nrc3599. PMID 24060863. S2CID 24719097.
Gillies RJ, Verduzco D, Gatenby RA (June 2012). "Evolutionary dynamics of carcinogenesis and why targeted therapy does not work". Nature Reviews. Cancer. 12 (7): 487–493. doi:10.1038/nrc3298. PMC 4122506. PMID 22695393.
Gatenby RA (May 2009). "A change of strategy in the war on cancer". Nature. 459 (7246): 508–509. Bibcode:2009Natur.459..508G. doi:10.1038/459508a. PMID 19478766. S2CID 205046753.
"CROSS resistance to antibiotics". Journal of the American Medical Association. 148 (6): 470–471. February 1952. doi:10.1001/jama.1952.02930060052015. PMID 14888510.
Santos-Lopez, Alfonso; Marshall, Christopher W; Haas, Allison L; Turner, Caroline; Rasero, Javier; Cooper, Vaughn S (25 August 2021). "The roles of history, chance, and natural selection in the evolution of antibiotic resistance". eLife. 10: e70676. doi:10.7554/eLife.70676. PMC 8412936. PMID 34431477.
Maltas J, Wood KB (October 2019). "Pervasive and diverse collateral sensitivity profiles inform optimal strategies to limit antibiotic resistance". PLOS Biology. 17 (10): e3000515. doi:10.1371/journal.pbio.3000515. PMC 6834293. PMID 31652256.
Acar A, Nichol D, Fernandez-Mateos J, Cresswell GD, Barozzi I, Hong SP, et al. (April 2020). "Exploiting evolutionary steering to induce collateral drug sensitivity in cancer". Nature Communications. 11 (1): 1923. Bibcode:2020NatCo..11.1923A. doi:10.1038/s41467-020-15596-z. PMC 7174377. PMID 32317663.
Enriquez-Navas PM, Kam Y, Das T, Hassan S, Silva A, Foroutan P, et al. (February 2016). "Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer". Science Translational Medicine. 8 (327). 327ra24. doi:10.1126/scitranslmed.aad7842. PMC 4962860. PMID 26912903.
Kim E, Brown JS, Eroglu Z, Anderson AR (February 2021). "Adaptive Therapy for Metastatic Melanoma: Predictions from Patient Calibrated Mathematical Models". Cancers. 13 (4): 823. doi:10.3390/cancers13040823. PMC 7920057. PMID 33669315.
Gatenby RA, Silva AS, Gillies RJ, Frieden BR (June 2009). "Adaptive therapy". Cancer Research. 69 (11): 4894–4903. doi:10.1158/0008-5472.CAN-08-3658. PMC 3728826. PMID 19487300.
Cunningham J, Brown J, Gatenby R, Stankova K (December 2018). "Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer". JAMA Oncology. 459: 67–78. Bibcode:2018JThBi.459...67C. doi:10.1016/j.jtbi.2018.09.022. PMID 30243754. S2CID 52340340.
Zhang J, Cunningham JJ, Brown JS, Gatenby RA (November 2017). "Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer". Nature Communications. 8 (1): 1816. Bibcode:2017NatCo...8.1816Z. doi:10.1038/s41467-017-01968-5. PMC 5703947. PMID 29180633.
Zhang J, Cunningham JJ, Brown JS, Gatenby RA (June 2022). "Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes". eLife. 11. doi:10.7554/eLife.76284. PMC 9239688. PMID 35762577.
Basanta D, Gatenby RA, Anderson AR (April 2012). "Exploiting evolution to treat drug resistance: combination therapy and the double bind". Mol Pharm. 9 (4): 914–921. doi:10.1021/mp200458e. PMC 3325107. PMID 22369188.
Gatenby R, Brown J, Vincent T (September 2014). "Lessons from applied ecology: cancer control using an evolutionary double bind". Cancer Research. 69 (19): 7499–7502. doi:10.1158/0008-5472.CAN-09-1354. PMID 19752088.
Gatenby RA, Artzy-Randrup Y, Epstein T, Reed DR, Brown JS (February 2021). "Eradicating Metastatic Cancer and the Eco-Evolutionary Dynamics of Anthropocene Extinctions". Cancer Research. 80 (3): 613–623. doi:10.1158/0008-5472.CAN-19-1941. PMC 7771333. PMID 31772037.
Gatenby RA, Zhang J, Brown JS (July 2019). "First Strike–Second Strike Strategies in Metastatic Cancer: Lessons from the Evolutionary Dynamics of Extinction". Cancer Research. 79 (13): 3174–3177. doi:10.1158/0008-5472.CAN-19-0807. PMC 6606376. PMID 31221821.
Wölfl B, Te Rietmole H, Salvioli M, Kaznatcheev A, Thuijsman F, Brown JS, et al. (2021). "The Contribution of Evolutionary Game Theory to Understanding and Treating Cancer". Dynamic Games and Applications. 12 (2): 313–342. doi:10.1007/s13235-021-00397-w. PMC 9117378. PMID 35601872. S2CID 239673089.
Zhang J, Cunningham JJ, Brown JS, Gatenby RA (November 2017). "Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer". Nature Communications. 8 (1): 1816. Bibcode:2017NatCo...8.1816Z. doi:10.1038/s41467-017-01968-5. PMC 5703947. PMID 29180633.
Mistry HB (January 2021). "On the reporting and analysis of a cancer evolutionary adaptive dosing trial". Nature Communications. 12 (1): 316. Bibcode:2021NatCo..12..316M. doi:10.1038/s41467-020-20174-4. PMC 7804309. PMID 33436546.

ncbi.nlm.nih.gov

Greaves M, Maley CC (January 2012). "Clonal evolution in cancer". Nature. 481 (7381): 306–313. Bibcode:2012Natur.481..306G. doi:10.1038/nature10762. PMC 3367003. PMID 22258609.
Davies J, Davies D (September 2010). "Origins and evolution of antibiotic resistance". Microbiology and Molecular Biology Reviews. 74 (3): 417–433. doi:10.1128/MMBR.00016-10. PMC 2937522. PMID 20805405.
Gillies RJ, Verduzco D, Gatenby RA (June 2012). "Evolutionary dynamics of carcinogenesis and why targeted therapy does not work". Nature Reviews. Cancer. 12 (7): 487–493. doi:10.1038/nrc3298. PMC 4122506. PMID 22695393.
Santos-Lopez, Alfonso; Marshall, Christopher W; Haas, Allison L; Turner, Caroline; Rasero, Javier; Cooper, Vaughn S (25 August 2021). "The roles of history, chance, and natural selection in the evolution of antibiotic resistance". eLife. 10: e70676. doi:10.7554/eLife.70676. PMC 8412936. PMID 34431477.
Maltas J, Wood KB (October 2019). "Pervasive and diverse collateral sensitivity profiles inform optimal strategies to limit antibiotic resistance". PLOS Biology. 17 (10): e3000515. doi:10.1371/journal.pbio.3000515. PMC 6834293. PMID 31652256.
Acar A, Nichol D, Fernandez-Mateos J, Cresswell GD, Barozzi I, Hong SP, et al. (April 2020). "Exploiting evolutionary steering to induce collateral drug sensitivity in cancer". Nature Communications. 11 (1): 1923. Bibcode:2020NatCo..11.1923A. doi:10.1038/s41467-020-15596-z. PMC 7174377. PMID 32317663.
Weaver, D. (2024). "Reinforcement Learning informs optimal treatment strategies to limit antibiotic resistance". Proceedings of the National Academy of Sciences. 121.16: e2303165121. doi:10.1073/pnas.2303165121. PMC 11032439.
Enriquez-Navas PM, Kam Y, Das T, Hassan S, Silva A, Foroutan P, et al. (February 2016). "Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer". Science Translational Medicine. 8 (327). 327ra24. doi:10.1126/scitranslmed.aad7842. PMC 4962860. PMID 26912903.
Kim E, Brown JS, Eroglu Z, Anderson AR (February 2021). "Adaptive Therapy for Metastatic Melanoma: Predictions from Patient Calibrated Mathematical Models". Cancers. 13 (4): 823. doi:10.3390/cancers13040823. PMC 7920057. PMID 33669315.
Gatenby RA, Silva AS, Gillies RJ, Frieden BR (June 2009). "Adaptive therapy". Cancer Research. 69 (11): 4894–4903. doi:10.1158/0008-5472.CAN-08-3658. PMC 3728826. PMID 19487300.
Zhang J, Cunningham JJ, Brown JS, Gatenby RA (November 2017). "Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer". Nature Communications. 8 (1): 1816. Bibcode:2017NatCo...8.1816Z. doi:10.1038/s41467-017-01968-5. PMC 5703947. PMID 29180633.
Zhang J, Cunningham JJ, Brown JS, Gatenby RA (June 2022). "Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes". eLife. 11. doi:10.7554/eLife.76284. PMC 9239688. PMID 35762577.
Basanta D, Gatenby RA, Anderson AR (April 2012). "Exploiting evolution to treat drug resistance: combination therapy and the double bind". Mol Pharm. 9 (4): 914–921. doi:10.1021/mp200458e. PMC 3325107. PMID 22369188.
Gatenby RA, Artzy-Randrup Y, Epstein T, Reed DR, Brown JS (February 2021). "Eradicating Metastatic Cancer and the Eco-Evolutionary Dynamics of Anthropocene Extinctions". Cancer Research. 80 (3): 613–623. doi:10.1158/0008-5472.CAN-19-1941. PMC 7771333. PMID 31772037.
Gatenby RA, Zhang J, Brown JS (July 2019). "First Strike–Second Strike Strategies in Metastatic Cancer: Lessons from the Evolutionary Dynamics of Extinction". Cancer Research. 79 (13): 3174–3177. doi:10.1158/0008-5472.CAN-19-0807. PMC 6606376. PMID 31221821.
Wölfl B, Te Rietmole H, Salvioli M, Kaznatcheev A, Thuijsman F, Brown JS, et al. (2021). "The Contribution of Evolutionary Game Theory to Understanding and Treating Cancer". Dynamic Games and Applications. 12 (2): 313–342. doi:10.1007/s13235-021-00397-w. PMC 9117378. PMID 35601872. S2CID 239673089.
Zhang J, Cunningham JJ, Brown JS, Gatenby RA (November 2017). "Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer". Nature Communications. 8 (1): 1816. Bibcode:2017NatCo...8.1816Z. doi:10.1038/s41467-017-01968-5. PMC 5703947. PMID 29180633.
Mistry HB (January 2021). "On the reporting and analysis of a cancer evolutionary adaptive dosing trial". Nature Communications. 12 (1): 316. Bibcode:2021NatCo..12..316M. doi:10.1038/s41467-020-20174-4. PMC 7804309. PMID 33436546.

semanticscholar.org

api.semanticscholar.org

Gatenby RA, Brown JS (November 2020). "Integrating evolutionary dynamics into cancer therapy". Nature Reviews. Clinical Oncology. 17 (11): 675–686. doi:10.1038/s41571-020-0411-1. PMID 32699310. S2CID 220681064.
Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (October 2013). "Cancer drug resistance: an evolving paradigm". Nature Reviews. Cancer. 13 (10): 714–726. doi:10.1038/nrc3599. PMID 24060863. S2CID 24719097.
Gatenby RA (May 2009). "A change of strategy in the war on cancer". Nature. 459 (7246): 508–509. Bibcode:2009Natur.459..508G. doi:10.1038/459508a. PMID 19478766. S2CID 205046753.
Cunningham J, Brown J, Gatenby R, Stankova K (December 2018). "Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer". JAMA Oncology. 459: 67–78. Bibcode:2018JThBi.459...67C. doi:10.1016/j.jtbi.2018.09.022. PMID 30243754. S2CID 52340340.
Wölfl B, Te Rietmole H, Salvioli M, Kaznatcheev A, Thuijsman F, Brown JS, et al. (2021). "The Contribution of Evolutionary Game Theory to Understanding and Treating Cancer". Dynamic Games and Applications. 12 (2): 313–342. doi:10.1007/s13235-021-00397-w. PMC 9117378. PMID 35601872. S2CID 239673089.

zenodo.org

Cunningham J, Brown J, Gatenby R, Stankova K (December 2018). "Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer". JAMA Oncology. 459: 67–78. Bibcode:2018JThBi.459...67C. doi:10.1016/j.jtbi.2018.09.022. PMID 30243754. S2CID 52340340.